BioPharma Resources

Drug Trial Radar · NCT07890350

Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy

A Randomized, Double-Blind, Placebo-Parallel Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2028

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy

Conditions

  • Perennial Allergic Rhinitis (PAR)

Interventions

  • CM512Biological

    Subcutaneous injection, multiple doses. Dosing every 12 weeks (Q12W) or Q24W, according to the protocol. Total treatment duration: 48 weeks.

  • PlaceboDrug

    Subcutaneous injection of matching placebo. multiple doses. Q12W or Q24W according to the protocol. Total treatment duration: 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 24Time frame: baseline, Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, CMU

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.